Home » Newsletters » BioWorld Science

BioWorld Science

March 29, 2011

View Archived Issues

Suzhou Ascepion Pharmaceuticals presents new protein kinase inhibitors for cancer

Aeterna Zentaris receives grant to develop cytotoxic conjugates and related diagnostic tools

Phase IIa trial of Addex's ADX-71149 begins in schizophrenia

Hexabrix demonstrates potential for the treatment of allergic rhinitis

SST-0001 suppresses growth of MM in vivo by inhibiting heparanase

Cephalon's H3 receptor antagonist/inverse agonist CEP-26401 identified as clinical candidate

IFNG and IFNGR1 gene variants linked to atopic dermatitis with eczema heperticum

Phase II data show reduced late asthmatic response with lebrikizumab treatment

GSK patents new AMPK activators

New Toll-like receptor agonists reported by Gilead

New hepcidin antagonists for anemia reported by Vifor

New Bcl-2-like protein inhibitors designed at Novartis

Array BioPharma scientists patent novel inhibitors of mTOR

Ventrus submits SPA with revised endpoints for phase III VEN-309 study

Ariad and MolecularMD collaborate on companion T315I mutation diagnostic test

GenSpera treats first patient in phase I G-202 trial

Data Monitoring Committee recommends continuing belinostat trial

Ablynx commences phase I/II study of ALX-0061 in rheumatoid arthritis

MolMed and Fondazione Telethon agree to develop gene therapy for six rare diseases

Onyx to modify phase III FOCUS study of carfilzomib in relapsed and refractory myeloma

Ono and OncoTherapy enter license agreement for therapeutic peptide vaccines for cancer

Alnylam earns technology transfer payment from Takeda

XTL Biopharmaceuticals set to gain antipsychotic drug candidates with acquisition of MinoGuard

Cephalon set to make takeover bid for ChemGenex Pharmaceuticals

Cellceutix signs confidential disclosure agreement pertaining to autism treatment KM-391

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...